NDA 018422 · Pfizer Pharms
Lopid
Gemfibrozil · Oral
NovelLast checked: Nov 20, 2026Latest source record: Dec 10, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1981
Dec 21, 1981
Approved uses
2
Original approval plus efficacy supplements
Registered trials
43
3 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 17, 1989 Supplement 22 · Efficacy
- Dec 21, 1981 Original approval · Type 1 - New Molecular Entity
3 products under this application
- LOPID · GEMFIBROZIL 600MG · TABLET, ORAL · Prescription · TE AB
- LOPID · GEMFIBROZIL 200MG · CAPSULE, ORAL · Discontinued
- LOPID · GEMFIBROZIL 300MG · CAPSULE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Gemfibrozil" as an intervention, any sponsor and status, largest first.
- The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-CholesterolPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT00283335 · 2,531 participants · Start Jun 1991 · Primary completion Sep 1998
Drug: gemfibrozil · For: Coronary Heart Disease
Sites: Minneapolis, Minnesota
- Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 DiabetesPivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00004266 · 160 participants · Start Aug 1993 · Primary completion Jul 1999
Drug: Lisinopril; Nifedipine and 1 more · For: Diabetic Nephropathy
Sites: Minneapolis, Minnesota
- Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive MedicinesPivotal-lookingStatus unknown
Pontificia Universidad Catolica de ChileAcademic, hospital or other
NCT01974544 · 150 participants (planned) · Start May 2013 · Primary completion Dec 2015
Drug: Best medical treatment; General interventions for all groups: blood presure and 1 more · For: Type 2 Diabetes
Sites: Santiago, Chile
Seagen Inc.Pfizer (PFE)
NCT03723395 · 116 participants · Start Sep 17, 2018 · Primary completion Dec 21, 2018
Drug: tucatinib; itraconazole and 6 more · For: Drug-drug Interaction
Sites: Daytona Beach, Florida; Dallas, Texas
- Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3APivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT03624959 · 100 participants · Start Jun 20, 2018 · Primary completion Aug 10, 2018
Drug: Ozanimod; Gemfibrozil and 2 more · For: Healthy Volunteer
Sites: Austin, Texas
- Early Therapeutic Effects of Statins and Fibrates on Unstable Atherosclerotic PlaquesPivotal-lookingWithdrawn
University Hospital MuensterAcademic, hospital or other
NCT00243672 · 100 participants (planned) · Start Oct 2005
Drug: Atorvastatin; Gemfibrozil · For: Atherosclerosis
National Institutes of Health Clinical Center (CC)NIH
NCT00039663 · 75 participants · Start May 2002
Drug: Pravastatin; Gemfibrozil and 1 more · For: HIV Infections
Sites: Bethesda, Maryland
Gregory Jicha, 323-5550Academic, hospital or other
NCT02045056 · 72 participants · Start May 2014 · Primary completion Jun 30, 2018
Drug: Gemfibrozil; Placebo · For: Preclinical Alzheimer's Disease
Sites: Lexington, Kentucky
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lopid (Gemfibrozil)
2024 spending
$2K
Beneficiaries
n/a
21 claims
Per beneficiary
n/a
$1.29 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $85,455 |
| 2021 | $102,053 |
| 2022 | $13,750 |
| 2023 | $7,633 |
| 2024 | $2,304 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Risk factors for anticoagulant-associated gastrointestinal hemorrhage: a systematic review and meta-analysis.
Ma F, Wu S, Li S, et al. · Korean J Intern Med 2024 · Meta-Analysis, Systematic Review
- Cholesterol reduction yields clinical benefits: meta-analysis including recent trials.
Gould AL, Davies GM, Alemao E, et al. · Clin Ther 2007 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Chinese herbal medicines for hypertriglyceridaemia.
Liu ZL, Li GQ, Bensoussan A, et al. · Cochrane Database Syst Rev 2013 · Research Support, Non-U.S. Gov't, Systematic Review
- Adverse effects of hypolipidaemic drugs.
Knodel LC, Talbert RL · Med Toxicol 1987 · Clinical Trial, Comparative Study
- Safety of fibrates in cholestatic liver diseases.
Carrion AF, Lindor KD, Levy C · Liver Int 2021 · Systematic Review
- Pharmacokinetic Drug Interaction Studies with Enzalutamide.
Gibbons JA, de Vries M, Krauwinkel W, et al. · Clin Pharmacokinet 2015 · Clinical Trial, Phase I, Clinical Trial, Phase III
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.